GO:0007171 activation of transmembrane receptor protein tyrosine kinase activity: Mechanism, Genes and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0007171 describes the biological process that switches an inactive transmembrane receptor protein tyrosine kinase (RTK) into its active state, typically through ligand-induced dimerization or oligomerization.
• RTK activation is a conserved signaling step that converts extracellular cues into intracellular phosphorylation cascades controlling growth, metabolism, and survival.
• The process can be triggered from the cell surface by ligands such as growth factors and neurotrophins, or experimentally from the cytoplasmic compartment.
• Dysregulated RTK activation is central to many cancers and metabolic disorders, making it a major therapeutic target.
• Key RTK families include insulin receptor (INSR), IGF1R, NTRK receptors, and PTK7, each with distinct activation mechanisms and disease links.
• CRISPR-based knockout, point-mutation, knock-in, and overexpression models enable precise interrogation of RTK activation in disease and development.
Description
Receptor tyrosine kinases (RTKs) are cell-surface receptors that initiate intracellular signaling in response to extracellular ligands. The Gene Ontology term GO:0007171, activation of transmembrane receptor protein tyrosine kinase activity, captures the step that converts an inactive RTK into a catalytically active kinase. This process is fundamental to metazoan physiology, as it governs cell proliferation, differentiation, survival, and metabolism. Understanding how RTKs become activated is therefore essential for both basic cell biology and therapeutic development. Mechanistically, RTK activation often begins with ligand binding, which stabilizes receptor dimers or higher-order oligomers and relieves autoinhibition of the kinase domain. This event triggers trans-autophosphorylation of tyrosine residues in the cytoplasmic tail, creating docking sites for downstream signaling proteins. In some contexts, activation can also be achieved from the cytoplasmic side, highlighting the diversity of regulatory inputs. The term GO:0007171 specifically refers to the initiation of kinase activity, distinguishing it from downstream signaling events. Because RTK activation is a nodal point in signaling, its dysregulation contributes to cancer, diabetes, and neurodevelopmental disorders. Researchers study this process using biochemical assays, structural biology, and CRISPR-based genetic models to define causal roles of specific RTKs and their regulators. The sections below synthesize current knowledge from authoritative literature and outline experimental strategies for investigating GO:0007171.
activation of transmembrane receptor protein tyrosine kinase activity At A Glance
| GO ID | GO:0007171 |
|---|---|
| GO term | activation of transmembrane receptor protein tyrosine kinase activity |
| Ontology | biological_process |
| Synonym | transmembrane receptor protein tyrosine kinase activation; transmembrane receptor protein tyrosine kinase dimerization |
| Major function | Initiates catalytic activity of inactive RTKs, enabling signal transduction from extracellular cues to intracellular phosphorylation |
| Cellular location | Plasma membrane and endomembranes; activation can also occur from the cytoplasmic compartment |
| Key triggers | Ligand binding, receptor dimerization/oligomerization, and conformational relief of autoinhibition |
| Representative receptors | INSR, IGF1R, NTRK1/2/3, PTK7, and other RTK families |
| Disease relevance | Cancer, metabolic disorders, and neurodevelopmental conditions |
What Is GO:0007171?
GO:0007171 is defined as any process that initiates the activity of an inactive transmembrane receptor protein tyrosine kinase. In practice, this includes ligand-induced dimerization, conformational changes that relieve autoinhibition, and trans-autophosphorylation events that convert the receptor into a catalytically competent enzyme. The term is a biological process and is distinct from the downstream signaling cascades that follow RTK activation.
Why Is activation of transmembrane receptor protein tyrosine kinase activity Important in Cell Biology?
RTK activation is a central control point in cell signaling, and its precise regulation is required for normal development and tissue homeostasis. Because activation is often the rate-limiting step in RTK signaling, mutations or expression changes that alter this process can drive oncogenesis or metabolic disease. Consequently, understanding GO:0007171 informs drug discovery, biomarker development, and the design of CRISPR-based disease models.
• RTK activation converts extracellular signals into intracellular phosphorylation, controlling proliferation and survival.
• Dysregulated RTK activation is a hallmark of many cancers, including those driven by PTK7 and other RTKs.
• Insulin receptor kinase activity is essential for metabolic regulation, and its dysfunction contributes to diabetes.
• IGF-1/IGF-1R activation mediates exercise-induced protection against skeletal muscle atrophy.
• Neurotrophin receptor activation, such as NTRK signaling, is critical for neuronal survival and plasticity.
• Exercise-induced factors like Nrg4 can modulate systemic signaling through RTK-related pathways.
• BDNF expression, linked to RTK signaling, is promoted by exercise via β-hydroxybutyrate.
• RTK activation can be targeted therapeutically with small-molecule inhibitors or antibodies.
• CRISPR screens can identify regulators of RTK activation and resistance mechanisms.
• Understanding RTK activation informs the development of precision medicine approaches.
What Happens During activation of transmembrane receptor protein tyrosine kinase activity?
Ligand binding and receptor dimerization
In simple terms: A signaling molecule binds to the outside of the receptor, causing two receptors to pair up.
The canonical activation of RTKs begins with ligand binding to the extracellular domain, which induces receptor dimerization or oligomerization. This dimerization brings the cytoplasmic kinase domains into close proximity, allowing them to phosphorylate each other. Different RTK families use distinct ligands, such as growth factors, insulin, and neurotrophins, to trigger this step. The ligand-bound state stabilizes the active conformation and is a prerequisite for downstream signaling.
Conformational relief of autoinhibition
In simple terms: The receptor changes shape to unlock its kinase domain.
Many RTKs are kept inactive by autoinhibitory interactions, such as the activation loop or juxtamembrane region blocking the kinase active site. Ligand-induced dimerization triggers conformational changes that relieve this autoinhibition, allowing ATP and substrate binding. For example, the insulin receptor undergoes a large conformational shift upon ligand binding to activate its kinase. This step is critical for converting the receptor from an off to an on state.
Trans-autophosphorylation
In simple terms: The paired receptors phosphorylate each other to fully activate.
Once dimerized, the kinase domains trans-phosphorylate tyrosine residues in the activation loop and cytoplasmic tail. This autophosphorylation further stabilizes the active conformation and creates docking sites for downstream signaling proteins containing SH2 or PTB domains. The phosphorylation events are a hallmark of RTK activation and are often used as readouts in experiments.
Cytoplasmic activation
In simple terms: Sometimes the receptor can be activated from inside the cell without an external signal.
In addition to ligand-driven activation at the plasma membrane, RTKs can be activated from the cytoplasmic compartment. This can occur through intracellular ligands, oxidative modifications, or interactions with cytoplasmic proteins that promote dimerization or conformational changes. Cytoplasmic activation expands the regulatory repertoire of RTKs and may contribute to disease when misregulated.
Downstream signal initiation
In simple terms: Activation sets off a chain of signals inside the cell.
Phosphorylated RTKs recruit adaptor proteins such as GRB2 and SHC, leading to activation of RAS-MAPK, PI3K-AKT, and other pathways. These cascades control gene expression, metabolism, and cell fate. The activation step (GO:0007171) is therefore the gateway to diverse biological outcomes, and its duration and intensity are tightly regulated.
Key Genes Involved in GO:0007171 activation of transmembrane receptor protein tyrosine kinase activity
The following genes encode receptors and signaling components directly implicated in RTK activation and its downstream effects.
| Gene | Major Role | Research Relevance |
|---|---|---|
| INSR | Insulin receptor tyrosine kinase; mediates metabolic signaling | Metabolic disease, diabetes research |
| IGF1R | IGF-1 receptor; promotes growth and survival | Muscle atrophy, cancer, exercise physiology |
| NTRK1 | Neurotrophin receptor; neuronal survival and differentiation | Neurodegeneration, pain, cancer |
| NTRK2 | BDNF receptor; synaptic plasticity and survival | Neuropsychiatric disorders, exercise-induced BDNF |
| NTRK3 | Neurotrophin-3 receptor; neuronal development | Neuroblastoma, developmental disorders |
| PTK7 | Pseudokinase RTK; regulates Wnt signaling and cell polarity | Cancer therapy target |
| EGFR | Epidermal growth factor receptor; proliferation and survival | Cancer, targeted therapy |
| ERBB2 | HER2 receptor; growth factor signaling | Breast and gastric cancer |
| FGFR1 | Fibroblast growth factor receptor; development and metabolism | Cancer, skeletal disorders |
| PDGFRA | Platelet-derived growth factor receptor; mesenchymal signaling | Cancer, fibrosis |
| MET | Hepatocyte growth factor receptor; migration and survival | Cancer, tissue regeneration |
| ALK | Anaplastic lymphoma kinase; neuronal development | Lymphoma, lung cancer |
| RET | GDNF receptor; neural crest development | Thyroid cancer, Hirschsprung disease |
| KDR | VEGFR2; angiogenesis | Cancer, cardiovascular disease |
| Nrg4 | Neuregulin-4; adipokine modulating metabolic signaling | MASLD, exercise biology |
| BDNF | Neurotrophic factor; synaptic plasticity | Exercise-induced cognitive benefits |
| GRB2 | Adaptor protein downstream of RTKs | Signal transduction research |
How Is activation of transmembrane receptor protein tyrosine kinase activity Regulated?
RTK activation is tightly regulated by multiple mechanisms. Ligand availability and affinity control the initiation step, while receptor internalization and degradation limit signal duration. Phosphatases such as PTP1B can dephosphorylate RTKs and attenuate signaling. In addition, feedback phosphorylation of RTKs by downstream kinases like PKC or Src can modulate their activity. Exercise-induced factors such as Nrg4 and BDNF can influence RTK-related pathways systemically, linking physiological state to RTK activation. These regulatory layers ensure that RTK signaling is context-dependent and reversible.
activation of transmembrane receptor protein tyrosine kinase activity and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| PTK7 | Cancer progression and metastasis | Knockout and overexpression in cancer cell lines |
| INSR | Diabetes and insulin resistance | Point-mutation knock-in in metabolic cell models |
| IGF1R | Muscle atrophy and cancer | Knockout in skeletal muscle cells |
| NTRK2 | Depression and neurodegeneration | Knock-in of BDNF-responsive mutations in neurons |
| EGFR | Lung cancer and glioblastoma | Point mutation (e.g., L858R) knock-in in lung cells |
Cancer
Constitutive activation of RTKs through mutations, gene amplification, or autocrine loops drives many cancers. For example, PTK7 is overexpressed in several malignancies and is being explored as a therapeutic target. Oncogenic mutations in EGFR, ALK, and other RTKs lead to ligand-independent activation, making them prime targets for tyrosine kinase inhibitors. Understanding GO:0007171 is therefore central to cancer precision medicine.
Metabolic disorders
The insulin receptor kinase is critical for glucose homeostasis, and impaired activation contributes to insulin resistance and diabetes. IGF-1/IGF-1R signaling mediates exercise-induced protection against muscle atrophy, highlighting the therapeutic potential of modulating RTK activation in metabolic disease. Nrg4, an exercise-induced adipokine, alleviates MASLD by disrupting cGAS-STING signaling, further linking RTK-related pathways to metabolic health.
Neurodegeneration and neuropsychiatric disorders
Neurotrophin receptors such as NTRK2 (TrkB) are essential for neuronal survival and plasticity. BDNF, the ligand for TrkB, is induced by exercise via β-hydroxybutyrate, and impaired BDNF-TrkB signaling is implicated in depression and neurodegenerative diseases. Modulating RTK activation in neurons is a promising strategy for neuroprotection.
From activation of transmembrane receptor protein tyrosine kinase activity-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does loss of RTK X abolish ligand-induced activation? | CRISPR knockout cell line |
| Does a specific mutation alter kinase activity? | Point-mutation knock-in |
| Can a tagged RTK track activation dynamics? | Tagged knock-in (e.g., GFP or HA) |
| Does overexpression of RTK Y drive oncogenic signaling? | Overexpression cell model |
| Which genes regulate RTK activation in a genome-wide screen? | CRISPR library screening |
| How does a disease-associated SNP affect RTK activation? | Knock-in of the SNP in isogenic cells |
How to Study the activation of transmembrane receptor protein tyrosine kinase activity Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Phospho-immunoblotting | RTK autophosphorylation levels | Validation of activation after ligand stimulation |
| Phospho-proteomics | Global tyrosine phosphorylation changes | Pathway discovery and drug response |
| FRET biosensors | Real-time RTK conformational changes | Live-cell activation kinetics |
| CRISPR knockout screens | Genes required for RTK activation | Identification of regulators and resistance genes |
| In vitro kinase assay | Catalytic activity of purified RTK domains | Mechanistic studies of mutations |
| Cryo-EM | Three-dimensional structures of RTK complexes | Understanding activation conformations |
| Co-immunoprecipitation | Protein-protein interactions of RTKs | Identification of signaling complexes |
| RNA-seq | Transcriptional changes downstream of RTK activation | Functional consequences of activation |
Phospho-proteomics and immunoblotting
Activation of RTKs is commonly measured by immunoblotting with phospho-specific antibodies against the activation loop or autophosphorylation sites. Phospho-proteomics can quantify global changes in tyrosine phosphorylation following ligand stimulation or genetic perturbation. These methods provide direct evidence of RTK activation status.
Live-cell imaging and FRET biosensors
Genetically encoded FRET biosensors can monitor RTK activation dynamics in live cells with high spatial and temporal resolution. Tagged knock-in receptors allow tracking of dimerization and internalization. These approaches are valuable for understanding the kinetics of GO:0007171 in real time.
CRISPR screens and functional genomics
Genome-wide CRISPR knockout or activation screens can identify genes that regulate RTK activation and downstream signaling. Such screens have uncovered modifiers of drug resistance and novel therapeutic targets. Combining screens with phospho-readouts enables systematic dissection of RTK activation networks.
Structural biology and biochemical reconstitution
X-ray crystallography and cryo-EM have revealed the conformational changes underlying RTK activation. In vitro kinase assays with purified receptor domains can measure catalytic activity and the effects of mutations. These methods provide mechanistic insights into GO:0007171.
How CRISPR Can Be Used to Study GO:0007171 activation of transmembrane receptor protein tyrosine kinase activity
Knockout
CRISPR knockout of an RTK gene eliminates the receptor, allowing researchers to test whether it is required for a specific biological process. For example, knocking out IGF1R in muscle cells can reveal its role in exercise-induced hypertrophy. Knockout models are also used to validate drug targets and identify compensatory pathways.
Point Mutation
Point mutations can mimic disease-associated variants or alter catalytic residues to study RTK activation mechanisms. For instance, introducing the kinase-inactivating mutation K1030R in INSR can abolish its kinase activity. Such models are essential for distinguishing correlation from causation in RTK signaling.
Knock-in
Knock-in of tagged or reporter versions of RTKs enables tracking of receptor localization, dimerization, and activation in live cells. Knock-in of disease-relevant mutations, such as EGFR L858R, creates isogenic models for drug testing. These models preserve endogenous regulation and are valuable for studying GO:0007171 in a physiological context.
Overexpression
Overexpression of an RTK or its ligand can drive constitutive activation and oncogenic transformation. This approach is useful for studying gain-of-function effects and for screening inhibitors. However, overexpression may bypass normal regulatory mechanisms, so results should be interpreted with caution.
How EDITGENE Supports activation of transmembrane receptor protein tyrosine kinase activity Research
Researchers studying activation of transmembrane receptor protein tyrosine kinase activity-related genes often need to determine whether a candidate gene is causally involved in receptor activation, downstream signaling, or disease phenotypes. EDITGENE provides a comprehensive suite of CRISPR-based services to generate precisely engineered cell models, enabling rigorous functional validation of RTK biology.
Contact EDITGENE today to design your custom CRISPR model for activation of transmembrane receptor protein tyrosine kinase activity research.
Frequently Asked Questions About activation of transmembrane receptor protein tyrosine kinase activity
What is GO:0007171?
GO:0007171 is the Gene Ontology term for activation of transmembrane receptor protein tyrosine kinase activity, the process that switches an inactive RTK into its active form.
What genes are involved in activation of transmembrane receptor protein tyrosine kinase activity?
Key genes include INSR, IGF1R, NTRK1/2/3, PTK7, EGFR, ERBB2, FGFR1, PDGFRA, MET, ALK, RET, and KDR, among others.
How does RTK activation occur?
It typically begins with ligand binding, receptor dimerization, relief of autoinhibition, and trans-autophosphorylation.
What diseases are linked to RTK activation?
Dysregulated RTK activation is linked to cancer, diabetes, muscle atrophy, and neurodegenerative disorders.
Can RTKs be activated from inside the cell?
Yes, activation from the cytoplasmic compartment has been described, expanding the regulatory mechanisms beyond ligand binding.
What is the role of insulin receptor kinase activity?
It mediates metabolic signaling, and its dysfunction contributes to insulin resistance and diabetes.
How is RTK activation studied in the lab?
Common methods include phospho-immunoblotting, phospho-proteomics, FRET biosensors, and CRISPR screens.
What CRISPR models are used to study RTK activation?
Knockout, point-mutation knock-in, tagged knock-in, and overexpression models are widely used.
What is the link between exercise and RTK activation?
Exercise induces factors like Nrg4 and BDNF that modulate RTK-related signaling pathways.
Why is PTK7 important in cancer?
PTK7 is overexpressed in several cancers and is being targeted therapeutically, making it a key RTK in oncology research.
Conclusion
GO:0007171, activation of transmembrane receptor protein tyrosine kinase activity, is a fundamental biological process that converts extracellular signals into intracellular phosphorylation cascades. Its precise regulation is essential for normal physiology, and its dysregulation underlies cancer, metabolic disorders, and neurological diseases. Advances in CRISPR-based models and phospho-proteomics continue to illuminate the mechanisms and therapeutic potential of RTK activation. EDITGENE provides end-to-end CRISPR services to help researchers dissect RTK activation with rigor and reproducibility. By combining knockout, knock-in, point-mutation, overexpression, and screening approaches, we empower discovery in this critical signaling node.
References
- 1. Chen M et al.. 2025. Exercise-induced adipokine Nrg4 alleviates MASLD by disrupting hepatic cGAS-STING signaling.. Cell Rep 44(2):115251 PMID: 39891907
- 2. Trenker R et al.. 2020. Receptor tyrosine kinase activation: From the ligand perspective.. Curr Opin Cell Biol 63:174-185 PMID: 32114309
- 3. Feng L et al.. 2022. Aerobic exercise and resistance exercise alleviate skeletal muscle atrophy through IGF-1/IGF-1R-PI3K/Akt pathway in mice with myocardial infarction.. Am J Physiol Cell Physiol 322(2):C164-C176 PMID: 34852207
- 4. Yamanashi Y et al.. 2012. Activation of receptor protein-tyrosine kinases from the cytoplasmic compartment.. J Biochem 151(4):353-9 PMID: 22343747
- 5. Sleiman SF et al.. 2016. Exercise promotes the expression of brain derived neurotrophic factor (BDNF) through the action of the ketone body β-hydroxybutyrate.. Elife 5 PMID: 27253067
- 6. Mottard K et al.. 2025. Therapeutic targeting of the protein tyrosine kinase-7 in cancer: an overview.. Oncologist 30(8) PMID: 39468753
- 7. Zhang W et al.. 2022. Activation of neurotrophin signalling with light‑inducible receptor tyrosine kinases.. Mol Med Rep 25(2) PMID: 35014690
- 8. Gammeltoft S et al.. 1986. Protein kinase activity of the insulin receptor.. Biochem J 235(1):1-11 PMID: 3017297
